The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of expanded genomic testing in lung adenocarcinoma (LUCA) on survival benefit: The Lung Cancer Mutation Consortium II (LCMC II) experience.
 
Dara Aisner
Honoraria - AstraZeneca; Clovis Oncology
Consulting or Advisory Role - Casdin Capital; Oxford Oncology
 
Lynette M. Sholl
Consulting or Advisory Role - Genentech
 
Lynne D Berry
No Relationships to Disclose
 
Eric B. Haura
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Boehringer Ingelheim; Ignyta; Janssen; Lilly
Patents, Royalties, Other Intellectual Property - Patent pending on PLA technology related to kinase inhibitor sensitivity biomarkers
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Suresh S. Ramalingam
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly/ImClone; Merck; Novartis
Travel, Accommodations, Expenses - AstraZeneca; EMD Serono; Pfizer
 
Bonnie S. Glisson
No Relationships to Disclose
 
Mark A. Socinski
Honoraria - Genentech
Consulting or Advisory Role - Genentech
Research Funding - Pfizer (Inst)
 
Saiama Naheed Waqar
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Lilly (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Spectrum Pharmaceuticals (Inst); Synermore biologics (Inst); Vertex (Inst); Xcovery (Inst)
 
Edward B. Garon
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Jeremy Paul Cetnar
No Relationships to Disclose
 
Katerina A Politi
Research Funding - AstraZeneca; Gilead Sciences; Kolltan Pharmaceuticals
Patents, Royalties, Other Intellectual Property - MolecularMD
 
Joan Schiller
No Relationships to Disclose
 
Michael R. Rossi
No Relationships to Disclose
 
Heidi Chen
No Relationships to Disclose
 
John D. Minna
No Relationships to Disclose
 
Ignacio Ivan Wistuba
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Clovis Oncology; GE Healthcare; Genecentric; Genentech/Roche; GlaxoSmithKline; Lilly; Lilly
Speakers' Bureau - Boehringer Ingelheim; Medscape; Pfizer
Research Funding - Bayer; Genentech; Jounce Therapeutics; Merck; Myriad Genetics; OncoPlex Diagnostics
 
Bruce E. Johnson
Stock and Other Ownership Interests - KEW
Honoraria - Chugai Pharma; Merck
Consulting or Advisory Role - Amgen; AstraZeneca; Biothera; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Clovis Oncology; Genentech; KEW; Lilly; Merck; Novartis; Otsuka; Puma Biotechnology; Transgene
Patents, Royalties, Other Intellectual Property - Dana-Farber Cancer Institute
Expert Testimony - Genentech
 
Mark G. Kris
Consulting or Advisory Role - ARIAD; Array BioPharma; AstraZeneca; Clovis Oncology; Daiichi Sankyo; Genentech/Roche; Pfizer; Threshold Pharmaceuticals
Research Funding - Pfizer (Inst); Puma Biotechnology (Inst)
 
Paul A. Bunn
No Relationships to Disclose
 
David J. Kwiatkowski
No Relationships to Disclose